myeloid neoplasm (Cancer)
Information
- Disease name
- myeloid neoplasm
- Disease ID
- DOID:0070004
- Description
- "A bone marrow cancer that is formed of any one of the bone marrow cells belonging to the granulocytic (neutrophil, eosinophil, basophil), monocytic/macrophage, erythroid, megakaryocytic and mast cell lineages." [url:http\://www.bloodjournal.org/content/bloodjournal/128/3/462.full.pdf, url:https\://www.ncbi.nlm.nih.gov/pubmed/19357394]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01371981 | Active, not recruiting | Phase 3 | Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | June 20, 2011 | September 30, 2027 |
| NCT03862157 | Active, not recruiting | Phase 1/Phase 2 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | February 27, 2019 | January 31, 2025 |
| NCT01307579 | Completed | Phase 3 | Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia | April 4, 2011 | June 30, 2020 |
| NCT02756572 | Completed | Phase 2 | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms | September 22, 2016 | July 1, 2020 |
| NCT03012672 | Completed | Phase 2 | Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm | December 30, 2016 | February 26, 2021 |
| NCT01817075 | Completed | Phase 3 | Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant | November 4, 2013 | March 31, 2020 |
| NCT00866918 | Completed | Phase 3 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia | March 9, 2009 | September 30, 2022 |
| NCT05796570 | Recruiting | Phase 2 | A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies | April 19, 2023 | September 1, 2029 |
| NCT04195945 | Recruiting | Phase 2 | CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | March 11, 2020 | December 31, 2027 |
| NCT05031897 | Recruiting | Phase 2 | Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | October 25, 2021 | October 1, 2024 |
| NCT05074316 | Recruiting | The Myeloid Neoplasms Biology and Outcome Project | March 10, 2020 | December 31, 2032 | |
| NCT05656248 | Recruiting | Phase 2 | Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms | January 17, 2023 | August 2028 |
| NCT04981821 | Recruiting | N/A | A Randomized Trial of a Mobile Health Exercise Intervention for Older Adults With Myeloid Neoplasms | January 3, 2022 | December 31, 2025 |
| NCT04797767 | Suspended | Phase 1 | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | February 4, 2022 | December 31, 2024 |
| NCT04526288 | Terminated | Phase 2 | CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease | August 9, 2021 | August 27, 2023 |
| NCT04196010 | Terminated | Phase 1 | Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms | May 8, 2020 | October 13, 2021 |
- Disase is a (Disease Ontology)
- DOID:4960